Garg Neeta, Padron Elizabeth Jordan, Rammohan Kottil W, Goodman Courtney Frances
Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
J Clin Med. 2022 Oct 18;11(20):6139. doi: 10.3390/jcm11206139.
Bruton's tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders.
布鲁顿酪氨酸激酶（BTK）是一种属于酪氨酸激酶家族的重要蛋白质，在正常和恶性B淋巴细胞及髓系细胞的细胞内信号传导、增殖、迁移和存活中起关键作用。对BTK在B细胞信号通路中作用的了解，促使BTK抑制剂（BTKi）的开发，作为髓系起源恶性肿瘤的有效治疗方法，并探索其作为其他癌症的有前景的治疗选择。鉴于其在B细胞受体信号传导中的核心功能，抑制BTK是治疗多种涉及异常B细胞功能的自身免疫性疾病的有吸引力的方法，包括系统性红斑狼疮（SLE）、类风湿性关节炎（RA）和多发性硬化症（MS）。在此，我们综述BTK在不同细胞信号通路中的作用、BTKi在B细胞恶性肿瘤中的开发及其在MS和其他自身免疫性疾病治疗中的新作用。
